JP2023524811A5 - - Google Patents

Info

Publication number
JP2023524811A5
JP2023524811A5 JP2022567556A JP2022567556A JP2023524811A5 JP 2023524811 A5 JP2023524811 A5 JP 2023524811A5 JP 2022567556 A JP2022567556 A JP 2022567556A JP 2022567556 A JP2022567556 A JP 2022567556A JP 2023524811 A5 JP2023524811 A5 JP 2023524811A5
Authority
JP
Japan
Prior art keywords
sequence
domain
antigen
numbers
nucleic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022567556A
Other languages
English (en)
Japanese (ja)
Other versions
JP7796044B2 (ja
JP2023524811A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/030973 external-priority patent/WO2021226289A2/en
Publication of JP2023524811A publication Critical patent/JP2023524811A/ja
Publication of JP2023524811A5 publication Critical patent/JP2023524811A5/ja
Application granted granted Critical
Publication of JP7796044B2 publication Critical patent/JP7796044B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022567556A 2020-05-05 2021-05-05 Cd70特異的融合タンパク質を使用したtcrリプログラミングのための組成物及び方法 Active JP7796044B2 (ja)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US202063020196P 2020-05-05 2020-05-05
US63/020,196 2020-05-05
US202063129718P 2020-12-23 2020-12-23
US63/129,718 2020-12-23
US202163147618P 2021-02-09 2021-02-09
US63/147,618 2021-02-09
US202163171751P 2021-04-07 2021-04-07
US63/171,751 2021-04-07
PCT/US2021/030973 WO2021226289A2 (en) 2020-05-05 2021-05-05 Compositions and methods for tcr reprogramming using cd70 specific fusion proteins

Publications (3)

Publication Number Publication Date
JP2023524811A JP2023524811A (ja) 2023-06-13
JP2023524811A5 true JP2023524811A5 (cg-RX-API-DMAC7.html) 2024-05-15
JP7796044B2 JP7796044B2 (ja) 2026-01-08

Family

ID=78468785

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022567556A Active JP7796044B2 (ja) 2020-05-05 2021-05-05 Cd70特異的融合タンパク質を使用したtcrリプログラミングのための組成物及び方法

Country Status (11)

Country Link
US (1) US20240252641A1 (cg-RX-API-DMAC7.html)
EP (1) EP4146233A4 (cg-RX-API-DMAC7.html)
JP (1) JP7796044B2 (cg-RX-API-DMAC7.html)
KR (1) KR20230020421A (cg-RX-API-DMAC7.html)
CN (1) CN115989033B (cg-RX-API-DMAC7.html)
AU (1) AU2021268953A1 (cg-RX-API-DMAC7.html)
BR (1) BR112022022353A2 (cg-RX-API-DMAC7.html)
CA (1) CA3177488A1 (cg-RX-API-DMAC7.html)
IL (1) IL297916A (cg-RX-API-DMAC7.html)
MX (1) MX2022013956A (cg-RX-API-DMAC7.html)
WO (1) WO2021226289A2 (cg-RX-API-DMAC7.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3770168A1 (en) 2015-05-18 2021-01-27 TCR2 Therapeutics Inc. Compositions and methods for tcr reprogramming using fusion proteins
AU2021410788A1 (en) * 2020-12-23 2023-08-03 TCR2 Therapeutics Inc. Compositions and methods for tcr reprogramming using fusion proteins
JP2025504501A (ja) * 2022-01-19 2025-02-12 上海恒潤達生生物科技股▲フン▼有限公司 抗cd70ナノボディ及びその応用
WO2023177821A2 (en) * 2022-03-16 2023-09-21 Myeloid Therapeutics, Inc. Binding domains and methods of use thereof
WO2024249346A1 (en) * 2023-05-26 2024-12-05 Editas Medicine, Inc. Crispr-related methods and compositions targeting cd70 expression
CN121299119B (zh) * 2025-12-15 2026-03-06 信纳克(北京)生化标志物检测医学研究有限责任公司 噬血细胞综合征克隆性免疫细胞检测试剂组合物及其应用

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2816379A1 (en) * 2010-10-27 2012-05-03 Baylor College Of Medicine Chimeric cd27 receptors for redirecting t cells to cd70-positive malignancies
CN122399016A (zh) * 2014-03-15 2026-07-17 诺华股份有限公司 使用嵌合抗原受体治疗癌症
EP3770168A1 (en) * 2015-05-18 2021-01-27 TCR2 Therapeutics Inc. Compositions and methods for tcr reprogramming using fusion proteins
US11173179B2 (en) * 2015-06-25 2021-11-16 Icell Gene Therapeutics Llc Chimeric antigen receptor (CAR) targeting multiple antigens, compositions and methods of use thereof
EP3380602A4 (en) * 2015-11-23 2019-09-25 Trustees of Boston University METHOD AND COMPOSITIONS RELATED TO CHIMERIC ANTIGEN RECEPTORS
US10392442B2 (en) * 2015-12-17 2019-08-27 Bristol-Myers Squibb Company Use of anti-PD-1 antibody in combination with anti-CD27 antibody in cancer treatment
CN110177803A (zh) * 2016-11-22 2019-08-27 T细胞受体治疗公司 用于使用融合蛋白进行tcr重新编程的组合物和方法
EP3583129B1 (en) * 2017-02-14 2021-11-03 Kite Pharma, Inc. Cd70 binding molecules and methods of use thereof
BR112020005938A2 (pt) * 2017-09-27 2020-11-17 University Of Southern California célula imune ou população de células imunes da mesma, célula efetora imune ou célula-tronco, célula que apresenta antígeno, polinucleotídeo recombinante, vetor, composição que compreende uma célula imune efetora ou uma célula-tronco, métodos para produzir uma célula efetora imune que expressa receptor imune de ocorrência não natural, para gerar uma população de células manipuladas por rna, para fornecer imunidade antidoença em um indivíduo, para tratar ou prevenir uma doença associada à expressão de um antígeno, e, uso
GB201800649D0 (en) * 2018-01-16 2018-02-28 Argenx Bvba CD70 Combination Therapy
MX2020008184A (es) * 2018-02-01 2020-09-22 Pfizer Receptores de antigeno quimericos dirigidos a cd70.
KR102879284B1 (ko) * 2018-08-29 2025-10-31 난징 레전드 바이오테크 씨오., 엘티디. 항-메소텔린 키메라 항원 수용체(car) 작제물 및 이의 용도
WO2020060593A1 (en) * 2018-09-21 2020-03-26 Harpoon Therapeutics, Inc. Conditionally active receptors
WO2021133959A2 (en) * 2019-12-24 2021-07-01 TCR2 Therapeutics Inc. Compositions and methods for gamma delta tcr reprogramming using fusion proteins
WO2022006451A2 (en) * 2020-07-02 2022-01-06 TCR2 Therapeutics Inc. Compositions and methods for tcr reprogramming using fusion proteins and pd-1 antibodies
AU2021410788A1 (en) * 2020-12-23 2023-08-03 TCR2 Therapeutics Inc. Compositions and methods for tcr reprogramming using fusion proteins
WO2022150831A1 (en) * 2021-01-07 2022-07-14 Innovative Cellular Therapeutics Holdings, Ltd. Car cells and polyspecific binding molecules for treating solid tumor
WO2022192286A1 (en) * 2021-03-09 2022-09-15 TCR2 Therapeutics Inc. Compositions and methods for tcr reprogramming using fusion proteins and rna interference
WO2022232277A1 (en) * 2021-04-27 2022-11-03 TCR2 Therapeutics Inc. COMPOSITIONS AND METHODS FOR TCR REPROGRAMMING USING FUSION PROTEINS AND TGFβR SWITCH

Similar Documents

Publication Publication Date Title
US20250092133A1 (en) Bispecific antibody constructs for cdh3 and cd3
JP7098629B2 (ja) 抗pd-1モノクローナル抗体、その製造方法及び用途
JP6879998B2 (ja) Cd70及びcd3に対する抗体構築物
JP6359372B2 (ja) DARPinを含む二重特異キメラ蛋白質
TWI769537B (zh) 標靶bcma的抗體、雙專一性抗體及其用途
TWI854953B (zh) 抗cd3抗體及含有該抗體的分子、及其製造方法
JP2021534762A5 (cg-RX-API-DMAC7.html)
JP2021510521A5 (cg-RX-API-DMAC7.html)
JP2022542543A5 (cg-RX-API-DMAC7.html)
JP2021508469A5 (cg-RX-API-DMAC7.html)
BR112019016204A2 (pt) anticorpo ou fragmento de ligação a antígeno do anticorpo, polinucleotídeo, vetor, célula, imunócito artificial, métodos para produzir um anticorpo ou um fragmento de ligação a antígeno do anticorpo, para produzir uma molécula que se liga ao cd3 humano e cd3 de macaco cinomolgo e ao gprc5d humano, composição medicinal para tratamento e/ou prevenção, moléculas tendo atividade de ligação a antígeno e que se ligam ao cd3 humano e cd3 de macaco cinomolgo e ao gprc5d humano, e, usos para preparar um medicamento para tratar e/ou prevenir um câncer, para induzir citotoxicidade para as células expressando gprc5d e para redirecionamento de células t para as células expressando gprc5d
JP2019533719A5 (cg-RX-API-DMAC7.html)
AU2016302580A1 (en) Antibody constructs for FLT3 and CD3
JP2018502050A5 (cg-RX-API-DMAC7.html)
CA3131036A1 (en) Cd3 antigen-binding fragment and application thereof
WO2023174396A1 (zh) 一种新型免疫调节剂的开发和应用
WO2022152290A1 (en) Novel anti-gremlin1 antibodies
JP2023511963A5 (cg-RX-API-DMAC7.html)
JP2024515560A5 (cg-RX-API-DMAC7.html)
JP2024535930A5 (cg-RX-API-DMAC7.html)
WO2023241656A1 (zh) 包含抗cldn18.2抗体的双特异性抗体、药物组合物及用途
WO2019230869A1 (ja) 抗ヒトtlr7抗体
JPWO2011007853A1 (ja) 癌特異的アイソフォームに対するモノクローナル抗体
AU2024295542A1 (en) Anti-fgfr2/pd-1 bispecific antibody
JP7808831B2 (ja) 抗cd26抗体とその応用